​
​

I-Mab (IMAB) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

I-Mab Revenue Highlights

Latest Revenue (Y)

$27.64M

Latest Revenue (Q)

$1.10M

Main Segment (Y)

Licensing and Collaboration

I-Mab Revenue by Period

I-Mab Revenue by Year

DateRevenueChange
2023-12-31$27.64M-112.48%
2022-12-31$-221.56M-351.70%
2021-12-31$88.03M-94.29%
2020-12-31$1.54B5042.23%
2019-12-31$30.00M-44.22%
2018-12-31$53.78M365.39%
2017-12-31$11.56M-

I-Mab generated $27.64M in revenue during NA 2023, up -112.48% compared to the previous quarter, and up 51.40% compared to the same period a year ago.

I-Mab Revenue by Quarter

DateRevenueChange
2023-12-31$1.10M-61.08%
2023-06-30$2.84M-100.16%
2022-12-31$-1.76B-22147.83%
2022-06-30$8.00M-100.53%
2021-12-31$-1.51B-198.06%
2020-12-31$1.54B100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2019-12-31--100.00%
2019-09-30$15.00M44.37%
2018-12-31$10.39M-52.80%
2018-09-30$22.01M-

I-Mab generated $1.10M in revenue during Q4 2023, up -61.08% compared to the previous quarter, and up 0.07% compared to the same period a year ago.

I-Mab Revenue Breakdown

I-Mab Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20
Supply Of Investigational Products$10.83M$28.10M$47.91M-
Licensing and Collaboration$16.81M$-249.66M$40.12M-
Grant---$10.00M

I-Mab's latest annual revenue breakdown by segment (product or service), as of Dec 23: Licensing and Collaboration (60.82%), and Supply Of Investigational Products (39.18%).

Quarterly Revenue by Product

Product/ServiceDec 22Jun 22Sep 20
Grant$18.90M$10.00M-
Licensing and Collaboration-$23.76M-
Supply Of Investigational Products-$28.10M-

I-Mab's latest quarterly revenue breakdown by segment (product or service), as of Dec 22: Grant (100.00%).

I-Mab Revenue Breakdown by Country

Quarterly Revenue by Country

CountryDec 22Jun 22Sep 20
Grant$18.90M$10.00M-
Licensing and Collaboration-$23.76M-
Supply Of Investigational Products-$28.10M-

I-Mab's latest quarterly revenue breakdown by geography, as of Dec 22: Grant (100.00%).

I-Mab Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
BGNEBeiGene$2.46B$929.17M
APLSApellis Pharmaceuticals$366.28M$176.57M
ASNDAscendis Pharma$266.72M$95.89M
BPMCBlueprint Medicines$249.38M$128.18M
KYMRKymera Therapeutics$78.59M$3.74M
NRIXNurix Therapeutics$76.99M$12.59M
KRYSKrystal Biotech$50.70M$83.84M
FHTXFoghorn Therapeutics$34.16M$7.81M
IMABI-Mab$27.64M$1.10M
RVMDRevolution Medicines, Inc. Warrant$11.58M-
STTKShattuck Labs$1.66M$1.61M
LYELLyell Immunopharma$130.00K$34.00K
DSGNDesign Therapeutics--
CGEMCullinan Oncology--
GRCLGracell Bio--
IMVTImmunovant--
ERASErasca--
GLUEMonte Rosa Therapeutics-$4.70M
AKROAkero Therapeutics--

IMAB Revenue FAQ

What is I-Mab’s yearly revenue?

I-Mab's yearly revenue for 2023 was $27.64M, representing a decrease of -112.48% compared to 2022. The company's yearly revenue for 2022 was $-222M, representing a decrease of -351.70% compared to 2021. IMAB's yearly revenue for 2021 was $88.03M, representing a decrease of -94.29% compared to 2020.

What is I-Mab’s quarterly revenue?

I-Mab's quarterly revenue for Q4 2023 was $1.1M, a -61.08% decrease from the previous quarter (Q2 2023), and a 0% increase year-over-year (Q4 2021). The company's quarterly revenue for Q2 2023 was $2.84M, a -100.16% decrease from the previous quarter (Q4 2022), and a -99.82% decrease year-over-year (Q4 2020). IMAB's quarterly revenue for Q4 2022 was $-1.764B, a -22147.83% decrease from the previous quarter (Q2 2022), and a 0% increase year-over-year (Q3 2020).

What is I-Mab’s revenue growth rate?

I-Mab's revenue growth rate for the last 3 years (2021-2023) was -68.60%, and for the last 5 years (2019-2023) was -7.85%.

What are I-Mab’s revenue streams?

I-Mab's revenue streams in c 23 are Supply Of Investigational Products, and Licensing and Collaboration. Supply Of Investigational Products generated $10.83M in revenue, accounting 39.18% of the company's total revenue, down -61.46% year-over-year. Licensing and Collaboration generated $16.81M in revenue, accounting 60.82% of the company's total revenue, down -106.73% year-over-year.

What is I-Mab’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of I-Mab was Licensing and Collaboration. This segment made a revenue of $16.81M, representing 60.82% of the company's total revenue.